Benzinga

Benzinga

Benzinga

jeudi, août 27

Abbott Laboratories

ABTNYSE
Trade with Public
Trade with Public
$111.59
-2.51-2.2%
À la clôture: Aug 27, 5:00 PM EST
$111.76
0.170.15%
Après les heures: 6:07 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatDividendesComparerOptionsRapport sur les stocks

Abbott Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Abbott Laboratories (ABT).

Price Target Range — 8 Quarters

Analyst Consensus — 22 Analysts

21Buy
1Hold
Consensus RatingBuy# Analysts22Avg. Consensus PT$129Upside to Avg. PT+15.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2026TD CowenJoshua JenningsPT RaiseBuy$115→$135
Aug 14, 2026CitigroupJoanne WuenschPT RaiseBuy$112→$125
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wolfe Research Upgrades Abbott Laboratories to Outperform, Announces $130 Price Target

Wolfe Research analyst Mike Polark upgrades Abbott Laboratories (NYSE:ABT) from Peer Perform to Outperform and announces $130 price target.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Abbott Laboratories, Lowers Price Target to $125

UBS analyst Patrick Wood maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $125.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $112

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and raises the price target from $108 to $112.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $118

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $115 to $118.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $110 to $120.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $112

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $109 to $112.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved